Bijelic, Maja (56807060700)Maja (56807060700)BijelicDjukic, Milan (23988377500)Milan (23988377500)DjukicVukomanovic, Vladislav (55881072000)Vladislav (55881072000)VukomanovicParezanovic, Vojislav (14325763000)Vojislav (14325763000)ParezanovicLazic, Milica (59569283700)Milica (59569283700)LazicPavlovic, Andrija (57204964008)Andrija (57204964008)PavlovicPopovic, Sasa (57200324005)Sasa (57200324005)PopovicParezanovic, Miro (57210203543)Miro (57210203543)ParezanovicStefanovic, Igor (23470878000)Igor (23470878000)StefanovicDjordjevic, Stefan (57192951203)Stefan (57192951203)DjordjevicNinic, Sanja (51864038300)Sanja (51864038300)NinicPrijic, Sergej (20734985500)Sergej (20734985500)PrijicBozic Cvijan, Bojana (56689582200)Bojana (56689582200)Bozic CvijanJovanovic, Ida (23989306000)Ida (23989306000)JovanovicBajcetic, Milica (15727461400)Milica (15727461400)Bajcetic2025-06-122025-06-122024https://doi.org/10.3390/jcm13174976https://www.scopus.com/inward/record.uri?eid=2-s2.0-85203974810&doi=10.3390%2fjcm13174976&partnerID=40&md5=575f39993f3d0d8caa540ef421b2ce50https://remedy.med.bg.ac.rs/handle/123456789/1025Background: The angiotensin-converting enzyme inhibitor (ACEI) enalapril is often administered to infants and young children with heart failure (HF) in various dosing regimens and formulations not adapted for their age. Methods: This prospective, two-center, open-label 8-week study evaluated an age-appropriate formulation of orodispersible minitablets (ODMTs) of enalapril (0.25 mg and 1 mg) in children aged 0 to 6 years with HF due to congenital heart disease. An age/weight-based dosing schedule was followed. Measures of echocardiographic parameters, blood pressure, heart rate, modified Ross score, and biochemistry were obtained over the 8-week period. The following two groups were assessed: ACEI-naïve and ACEI-pretreated patients. Results: In total, 53 children (age range of 0.05 to 4.8 years) were enrolled and 29 were ACEI-naïve. The average enalapril dose was 0.098 mg/kg (0.06–0.17 mg/kg) in the naïve group and 0.15 mg/kg (0.07–0.3 mg/kg) in pretreated patients. After 8 weeks, the modified Ross score and left ventricular diastolic dimension (LVD) z-score showed a significant decrease in both groups (p < 0.005). During 8 weeks follow-up, there were no difference in the z-scores for the systolic blood pressure (p = 0.071) or heart rate (p = 0.146). Conclusions: Pediatric patients treated with ODMTs of enalapril for 8 weeks had favorable improvements in LVD and HF symptoms. © 2024 by the authors.ACEIscongenital heart diseaseenalaprilheart failureorodispersible minitabletspediatric cardiology